The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Filgrastim (r-metHuG-CSF): the first 10 years
Open accessAbstract
T HAS BEEN KNOWN for at least three decades that very specific factors control hematopoiesis, acting on early cells in the hematopoietic system to produce mature, functional cells. The isolation, purification, and cloning of these factors has lead to a new class of therapeutic agents, including the colony-stimulating factors and interleukins. This review is devoted to granulocyte colony-stimulating factor (G-CSF), specifically Filgrastim (r-metHuG-CSF), the bacterially synthesized recombinant protein form of GCSF, that acts on neutrophils, the body's major defense against infections. The purification and molecular cloning of Filgrastim were performed between 1984 and 1986,L-3 and the clinical development of Filgrastim commenced in 1986, with approval for clinical use in cancer patients treated with chemotherapy4 obtained in the United States in February 1991. In the 5 years since its approval, 1.2 million patients have been treated with Filgrastim (Amgen [Thousand Oaks, CA], data on file). Filgrastim was initially used as an adjunct to chemotherapy for ameliorating neutropenia, one of the major side effects of cancer chemotherapy. Its use has led to reduced infections and hospital admissions for patients with cancer. Besides chemotherapy-induced neutropenia, Filgrastim has been approved in more than 70 countries for the treatment of myelosuppression after bone marrow transplantation, severe chronic neutropenia (SCN), acute leukemia, aplastic anemia (AA), myelodysplastic syndromes (MDS), and mobilization of peripheral blood progenitor cells (PBPCs) for transplantation. The use of Filgrastim has made possible delivery of full-dose chemotherapy and high-dose chemotherapy and has benefited patients who are immunocompromised. A second form of rHuG-CSF (lenograstim) received approval in Europe in 1993. The biologic properties of Filgrastim and lenograstim are similar and are given in Table 1. This review focuses on Filgrastim and reviews the first 10 years of clinical development and the first 5 years of postapproval use as well as additional potential clinical applications. PHARMACOLOGY OF FlLGRASTlM The pharmacodynamics and pharmacokinetics of Filgrastim were studied in rodents',' and primates. and then in normal volunteers and in patients with malignant disease. The results of these studies indicated that Filgrastim had a consistent and predictable pharmacologic profile when ad
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Bezwoda, W. R., Seymour, L., & Dansey, R. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2483 · Cited by 400
RetractedBrugger, W., Heimfeld, S., Berenson, R. J., Mertelsmann, R., & Kanz, L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508033330503 · Cited by 345
RetractedCrawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., Kris, M., Grous, J., Picozzi, V., Rausch, G., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250305 · Cited by 1,390
Bone, R. C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-6-457 · Cited by 1,368
Souza, L., Boone, T., Gabrilove, J., Lai, P., Zsebo, K., Murdock, D., Chazin, V., Bruszewski, J., Lu, H., Chen, K., et al. (1986) · Science · doi:10.1126/science.232.4746.61 · Cited by 1,266
Self-citationGranulocyte colony-stimulating factor and its receptor
Demetri, G., & Griffin, J. (1991) · Blood · doi:10.1182/blood.v78.11.2791.2791 · Cited by 1,064
Lieschke, G., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., Fowler, K., Basu, S., Zhan, Y., & Dunn, A. (1994) · Blood · doi:10.1182/blood.v84.6.1737.1737 · Cited by 962
Gabrilove, J. L., Jakubowski, A., Scher, H., Sternberg, C., Wong, G., Grous, J., Yagoda, A., Fain, K., Moore, M. A. S., Clarkson, B., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806023182202 · Cited by 938
Self-citationSheridan, W. P., Fox, R. M., Begley, C. G., Maher, D., McGrath, K. M., Begley, C. G., Juttner, C. A., To, L. B., Szer, J., & Mostyn, G. (1992) · The Lancet · doi:10.1016/0140-6736(92)90795-5 · Cited by 857
Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor
Nagata, S., Tsuchiya, M., Asano, S., Kaziro, Y., Yamazaki, T., Yamamoto, O., Hirata, Y., Kubota, N., Oheda, M., Nomura, H., et al. (1986) · Nature · doi:10.1038/319415a0 · Cited by 812
Cited by
Kuderer, N. M., Dale, D. C., Crawford, J., & Lyman, G. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8823 · Cited by 720
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 643
Green, M. D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., Siena, S., Lalisang, R. I., Samonigg, H., Clemens, M. R., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg019 · Cited by 586
Holmes, F. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.727 · Cited by 537
Metcalf, D. (2008) · Blood · doi:10.1182/blood-2007-03-079681 · Cited by 528
Metadata
- Authors
- Welte, K., Gabrilove, J., Bronchud, M., Platzer, E., & Morstyn, G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1996-09-15
- Volume
- 88
- Issue
- 6
- Pages
- 1907-1929
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W202042235
- Cited by
- 599
- References
- 64
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Filgrastim (r-metHuG-CSF): the first 10 years. https://app.cochat.ai/papers/10.1182/blood.v88.6.1907.bloodjournal8861907
- The paper
- Welte, K., Gabrilove, J., Bronchud, M., Platzer, E., & Morstyn, G. (1996). Filgrastim (r-metHuG-CSF): the first 10 years. Blood. https://doi.org/10.1182/blood.v88.6.1907.bloodjournal8861907
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.